Research Topics
| Nicole M KudererSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators |
Detail Information
Publications
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsNicole M Kuderer
James P. Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester, New York 14642, USA
Cancer 106:2258-66. 2006..These factors may be useful in identifying patients at increased risk of serious medical complications and mortality for more aggressive supportive care measures...- Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic reviewNicole M Kuderer
University of Rochester School of Medicine and Dentistry, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
J Clin Oncol 25:3158-67. 2007..Several RCTs have been published recently that investigate the impact of G-CSF on mortality and relative dose-intensity (RDI)... - A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complicationsNicole M Kuderer
James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
Cancer 110:1149-61. 2007.... - Impact of venous thromboembolism and anticoagulation on cancer and cancer survivalNicole M Kuderer
Division of Hematology, Oncology and Cellular Therapy, Duke Comprehensive Cancer Center, Duke University Medical Center, DUMC 3841, Durham, NC 27710, USA
J Clin Oncol 27:4902-11. 2009..Although the LMWHs and related agents hold promise for improving outcomes in patients with cancer, additional studies of their efficacy and safety in this setting are needed... - CYP2D6 testing in breast cancer: ready for prime time?Nicole M Kuderer
Division of Hematology, Oncology and Cellular Therapy, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina 27710, USA
Oncology (Williston Park) 23:1223-32. 2009..Anticipated data from retrospective analysis of large adjuvant randomized trials of tamoxifen should help address the clinical utility of CYP2D6 testing... - Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapyGary H Lyman
Department of Medicine, Duke University, Durham, North Carolina 27710, USA
Cancer 117:1917-27. 2011..A prospective cohort study was undertaken to develop and validate a risk model for neutropenic complications in cancer patients receiving chemotherapy... - Development and validation of a predictive model for chemotherapy-associated thrombosisAlok A Khorana
James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, NY, USA
Blood 111:4902-7. 2008..5 months (C-statistic = 0.7 for both cohorts). This model can identify patients with a nearly 7% short-term risk of symptomatic VTE and may be used to select cancer outpatients for studies of thromboprophylaxis... - Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practiceJeffrey Crawford
Duke University, Durham, North Carolina, USA
J Natl Compr Canc Netw 6:109-18. 2008..Despite frequent planned reductions from standard RDI, the incidence of FN remains high in community oncology practice in the United States. Improved methods of pretreatment assessment of patient risk factors for neutropenia are needed... - Thromboembolism in hospitalized neutropenic cancer patientsAlok A Khorana
James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
J Clin Oncol 24:484-90. 2006..We investigated venous and arterial thromboembolism and associated outcomes in hospitalized cancer patients actively receiving therapy, as identified by neutropenia... - Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studiesGary H Lyman
Department of Medicine, James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
Cancer 109:1011-8. 2007..The predictive accuracy for treatment efficacy also underwent validation in 651 patients randomized on NSABP B-20 and 645 patients on NSABP B-14... - Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic reviewGary H Lyman
Duke University and Duke Comprehensive Cancer Center, 2424 Erwin Rd, Ste 205, Durham, NC 27705, USA
J Clin Oncol 28:2914-24. 2010.... - Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patientsAlok A Khorana
James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, New York 14642, USA
Cancer 110:2339-46. 2007..In the current study, the frequency, risk factors, and trends associated with VTE were examined among hospitalized cancer patients... - Cost effectiveness of myeloid growth factors in cancer chemotherapyGary H Lyman
Department of Medicine, University of Rochester and the James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
Curr Hematol Rep 2:471-9. 2003..Continuing clinical and economic evaluation, along with an updating of clinical practice guidelines because of rapid technologic and clinical advances, is encouraged... - Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapyGregory C Connolly
James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, NY, USA
Thromb Res 126:113-8. 2010..Leukocytosis has been associated with thrombosis and mortality in cancer patients. We explored the association of leukocytosis with venous thromboembolism (VTE) and early mortality in cancer patients initiating chemotherapy... - Cancer and thrombosis: back to the future renewed interest in an old problemGary H Lyman
Duke University and Duke Comprehensive Cancer Center, Durham, NC 27705, USA
Cancer Invest 27:472-3. 2009..Additional investigation into these and related questions should represent a high priority area for future basic and translational cancer research... - Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patientsGary H Lyman
Health Services and Outcomes Research Progam, James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
Curr Opin Hematol 9:207-14. 2002..Continuing clinical and economic evaluation along with an updating of clinical practice guidelines especially related to elderly patients is recommended because of rapid technologic and clinical advances... - Filgrastim in patients with neutropenia: potential effects on quality of lifeGary H Lyman
Health Services and Outcomes Research Program, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Drugs 62:65-78. 2002..Additional prospective controlled trials that contain quality-of-life issues as endpoints are needed... - American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancerGary H Lyman
Duke University Medical Center, University of Rochester Medical Center, Rochester, USA
J Clin Oncol 25:5490-505. 2007..To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer... - The strengths and limitations of meta-analyses based on aggregate dataGary H Lyman
Department of Medicine, University of Rochester, Medical Center, Rochester, New York 14642, USA
BMC Med Res Methodol 5:14. 2005..Few would disagree that meta-analyses based on individual patient data (IPD) offer several advantages and represent the standard to which all other systematic reviews should be compared... - Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysisGary H Lyman
University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Clin Breast Cancer 7:372-9. 2006..The analysis reported here reviews test performance characteristics of reported gene expression signatures in women with breast cancer... - Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysisGary H Lyman
Center for Health Outcomes and PharmacoEconomic Research, Albany Medical College, State University of New York, Albany, NY, USA
Am J Med 112:406-11. 2002..8). CONCLUSION: In this meta-analysis, recombinant colony-stimulating factors were effective in reducing the risk of febrile neutropenia and documented infection associated with several malignancies and dose-intensive treatment regimens... - Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspectiveLeon E Cosler
Albany College of Pharmacy, Albany, New York, USA
Pharmacoeconomics 25:343-51. 2007..This analysis presents the potential cost implications of G-CSF treatment for established neutropenia among hospitalised patients...